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Abstract
Adiponectin secreted from the adipocytes plays pleiotrop‐
ic, anti-atherosclerotic roles, such as enhancement of
insulin secretion and an increase in energy expenditure.
The measurement of levels of circulating adiponectin is
useful to evaluate the progression of atherosclerosis-
related diseases, such as coronary artery disease (CAD),
cerebral infarction (CI) and diabetes mellitus (DM). We
examined the serum antibody levels against recombinant
adiponectin protein via the amplified luminescent proxim‐
ity homogeneous assay-linked immunosorbent assay
(AlphaLISA) method. The results revealed that the anti‐
body levels were significantly higher in patients with CAD,
CI and type 2 DM, than in healthy donors. Receiver
operating curve analysis showed that the sensitivity was in
a range of 41–48% for CAD, CI and DM. Thus, the serum
anti-adiponectin antibody levels could be a common
marker for atherosclerosis-related diseases.
Keywords Atherosclerosis, Cardiovascular Disease,
Cerebral Infarction, Diabetes Mellitus, Antibody Biomark‐
er
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Abbreviations
ACI: acute cerebral infarction
AMI: acute myocardial infarction
AUC: area under the curve
CAD: coronary artery disease
DM: diabetes mellitus
HD: healthy donor
ROC: receiver operating curve.
1. Introduction
Adiponectin is a peptide hormone that plays a variety of
roles in glucose and lipid metabolism, diabetes (DM) and
metabolic syndrome [1–4]. The circulating adiponectin
level is negatively correlated with obesity, coronary artery
disease (CAD) and metabolic disorders [5,6]. Adiponectin
reduces atherosclerosis in apolipoprotein E-deficient mice
[7]. Furthermore, exacerbation of heart failure was ob‐
served in adiponectin-deficient mice [8]. AdipoR1 and
AdipoR2 are the major typical receptors of adiponectin,
and depletion of both receptors leads to insulin resistance
and glucose intolerance [9]. These results support the idea
that adiponectin has a causal role in suppressing the
development of diabetes mellitus (DM), CAD and athero‐
sclerosis.
We have recently reported novel atherosclerosis-related
antibody markers, such as antibodies against RPA2 for
stroke [10], antibodies against SOSTDC1 and TUBB2C for
CI and DM [11,12], and antibodies against ATP2B4 and
BMP-1 for atherosclerosis-related diseases, such as CI,
CAD, DM and chronic kidney disease [13]. Abnormality of
the blood vessels may result in the leaking out of the
antigenic proteins that can produce these antibodies. In the
present study, the levels of autoantibody against those of
adiponectin were examined. Our results showed that the
antibody levels were associated with CAD, CI and DM.
2. Methods
2.1 Sera of patients and healthy donor (HD) subjects
The Local Ethical Review Board of Chiba University,
Graduate School of Medicine (Chiba, Japan) as well as those
of co-operating hospitals approved the study. Sera were
collected from patients after they had provided written
informed consent. Each serum sample was centrifuged at
3,000 × g for 10 min, and supernatants were stored at -80˚C
until use. The serum samples of CAD, including acute
myocardial infarction (AMI), were obtained from the Kyoto
University Hospital. The samples of acute cerebral infarc‐
tion (ACI) were obtained from Chiba Rosai Hospital and
Chiba Aoba Municipal Hospital. The samples of type 2 DM
were obtained from Chiba University Hospital. Sera from
HD subjects were obtained from Chiba University, Chiba
Prefectural Sawara Hospital and Port Square Kashiwado
Clinic.
2.2 Amplified Luminescence Proximity Homogeneous Assay
(AlphaLISA)
The antigen used for the analysis of CAD and ACI speci‐
mens was recombinant His-tag-conjugated, full-length
adiponectin protein (ProSpec-Tany TechnoGene Ltd., Ness
Ziona, Israel). The antigen used for the analysis of age-
matched AMI and DM specimens was His-tag-conjugated
adiponectin peptide (amino acids 108-244) (ATGen Co.
Ltd., Seongnam, South Korea). AlphaLISA was performed
using 384-well microtitre plates (white opaque OptiPlate™,
Perkin Elmer, Waltham, MA) containing 2.5 µL of 1/100-
diluted sera and 2.5 µL of His-tag adiponectin (10 µg/mL)
in AlphaLISA buffer (25 mM HEPES, pH 7.4, 0.1% casein,
0.5% Triton X-100, 1 mg/mL dextran-500 and 0.05%
Proclin-300). The reaction mixture was incubated at room
temperature for 6–10 h. Nickel-chelate donor beads (2.5 µL
of 40 µg/mL) and anti-human IgG-conjugated acceptor
beads (2.5 µL of 40 µg/mL) were then added and incubated
further for seven to 21 days at room temperature in the
dark. The chemical emission was read on an EnSpire Alpha
microplate reader (PerkinElmer) as previously described
[11–13]. Specific reactions were calculated by subtracting
Alpha values without antigens from the values of adipo‐
nectin proteins.
2.3 Statistical Analyses
Student's t test and the Mann-Whitney U test were used to
determine the significance of the differences between the
two groups. The correlation was examined via Spearman’s
correlation analysis. All statistical analyses were carried
out using GraphPad Prism 5 (GraphPad Software, La Jolla,
CA). The predictive values of markers for diseases were
assessed by receiver operating curve (ROC) analysis, and
the cut-off values were set at the values that maximize the
sums of the sensitivity and specificity. All tests were two-
tailed and a P value below 0.05 was considered significant.
3. Results
3.1 Levels of adiponectin antibodies (adiponectin-Abs) are
associated with CAD
We examined the relationship between adiponectin-Abs
and CAD, which included sera from AMI and unstable
angina patients obtained from Kyoto University Hospital.
HD subjects from Kashiwado Clinic and Chiba Prefectural
Sawara Hospital were selected as those who had no
apparent abnormality on regular health check-ups, includ‐
ing those based on MRI examination. The average ages of
the HD subjects and patients were 49.8 and 66.6, respec‐
tively. The results of AlphaLISA showed that the levels of
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serum adiponectin-Abs were significantly higher in
patients with CAD than those in the HD subjects (Figure
1a). When the cut-off value was determined as the average
+ 2SD of the HD specimens, the positive rates of adiponec‐
tin-Abs in HD subjects and patients with CAD were 6.8%
and 17.7%, respectively (Table 1). Receiver operating curve
(ROC) analysis was carried out to evaluate the ability of
these markers to detect CAD. The areas under the curve
(AUCs) of adiponectin-Abs for CAD were 0.649 (95% CI:
0.603-0.695) (Figure 1b). When the cut-off value of the
adiponectin-Ab level was determined to be 3,020, the
sensitivity and specificity of the antibody level for the
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Figure 1. Comparison of serum adiponectin antibodies (adiponectin-Ab)
levels between the healthy donor (HD) subjects and patients with coronary
artery disease (CAD). Serum antibody levels examined by AlphalLISA are
shown by a box-whisker plot (a). The box plots display the 10th, 20th, 50th,
80th and 90th percentiles. P values as compared to the HD specimens are
shown. Receiver operating curve (ROC) analysis was carried out for
assessing the ability of adiponectin-Abs to detect CAD (b). Numbers in the
curves indicate cut-off values of marker levels and those in parentheses
indicate sensitivity (left) and specificity (right). P values of ROC analysis,
areas under the curve (AUC) and a 95% confidence interval (CI) are also
shown.
We then compared the antibody levels between the HD
subjects and age-matched patients with AMI. The average
ages of the HD subjects and the patients were 57.9 and 57.2,
respectively. The levels of adiponectin-Abs were also
significantly higher in patients with AMI as compared with
age-matched HD subjects (Table 1). The positive rates in the
HD subjects and patients with AMI were 4.7% and 14.1%,
respectively. ROC analysis revealed that the AUC of
adiponectin-Abs in patients with AMI was 0.641 (95% CI:
0.574-0.709). The sensitivity and specificity of the antibody
level for diagnosis of AMI were calculated to be 47.7% and
74.2%, respectively.
3.2 Levels of adiponectin-Abs are increased in patients with ACI
We next examined adiponectin-Ab levels in the sera of the
HD subjects obtained from Chiba University and Chiba
Prefectural Sawara Hospital, and in the sera of patients
with ACI obtained from Chiba Rosai Hospital and Chiba
Aoba Municipal Hospital. The average ages of the HD
subjects and the patients were 44.3 and 69.3, respectively.
(Figure 2a). The positive rates of adiponectin-Abs in the HD
subjects and patients with ACI were 2.8% and 30.4%,
respectively (Table 1). ROC analysis revealed that the AUC
of adiponectin-Abs for ACI was 0.652 (95% CI: 0.595-0.710;
Figure 2b). When the cut-off value of the adiponectin-Ab
level was determined to be 2,933, the sensitivity and
specificity of the antibody level for the diagnosis of ACI
were 46.2% and 86.1%, respectively.
Because the average ages of the HD subjects and the
patients were different, the antibody levels of age-matched
specimens were compared after depletion of the appropri‐
ate samples. The average ages of the HD subjects and the
patients selected were 50.8 and 51.0, respectively. Despite
the decrease in sample numbers examined, the levels of
CAD AMI, age-matched ACI ACI, age-matched DM, age-matched
HD Average 2,526 1,310 2,535 2,492 959
SD 640 455 368 383 673
Cut-off Value 3,805 2,219 3,272 3,257 2,306
Total No. 191 127 72 44 128
Positive No. 13 6 2 2 6
Positive Rate (%) 6.8% 4.7% 2.8% 4.5% 4.7%
Patient Average 3,087 1,679 3,045 2,813 1,392
SD 1,368 550 1,078 896 1,076
Total No. 378 128 286 54 128
Positive No. 67 18 87 11 12
Positive Rate (%) 17.7% 14.1% 30.4% 20.4% 9.4%
P value (Patient vs. HD) 6.2E-11 1.6E-08 1.5E-10 2.4E-02 1.5E-04
Table 1. Comparison of serum anti-adiponectin antibody levels between the HD subjects and ACI, age-matched ACI, CAD, age-matched AMI and age-matched
type 2 DM patients, examined by AlphaLISA. The table shows averages, SDs, cut-off values (average + 2SD), total sample numbers, the numbers of positive
sera of which antibody levels were higher than the cut-off value and the positive rates (%) of the HD subjects; averages, SDs, total sample numbers, numbers
of positive sera of which the antibody levels were higher than the cut-off value and the positive rates (%) of patients; and P values of the statistical comparison
between the HD subjects and patients.
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adiponectin-Abs were still significantly higher in patients
with ACI than in the HD subjects (P = 0.024; Table 1). The
positive rates of adiponectin-Abs in the HD subjects and
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Figure 2. Comparison of serum adiponectin-Ab levels between the HD
subjects and patients with acute cerebral infarction (ACI). Serum antibody
levels examined by AlphalLISA are shown by a box-whisker plot as
described in the legend to Figure 1. The results were also evaluated by ROC
analysis (b).
3.3 Levels of adiponectin-Abs are related to DM
Because atherosclerosis is closely related to type 2 DM, we
then compared the specimens of the HD subjects and age-
matched patients with type 2 DM obtained from Kashiwa‐
do Clinic and Chiba University Hospital, respectively. The
average ages of the HD subjects and the patients were 57.8
and 58.5, respectively. The levels of adiponectin-Abs were
higher in patients with DM than in the HD subjects (Figure
3a). The positive rates of adiponectin-Abs in the HD
subjects and patients with DM were 4.7% and 9.4%,
respectively (Table 1). ROC analysis revealed that the AUC
of adiponectin-Abs for DM was 0.646 (95% CI: 0.579-0.713)
(Figure 3b). The sensitivity and specificity of the antibody




























Figure 3. Comparison of serum adiponectin-Ab levels between the HD
subjects and patients with type 2 diabetes mellitus (DM). Serum adiponec‐
tin-Ab levels examined by AlphalLISA are shown by a box-whisker plot as
described in the legends of Figure 1 (a). The results were also evaluated by
ROC analysis (b).
4. Discussion
Recent studies have shown that autoantibodies develop
and increase, not only in instances of autoimmune diseases
and cancer but also in other metabolic and vascular
diseases, such as autoantibodies to oxidized low-density
lipoprotein and β2-glycoprotein I in atherosclerosis [14,15],
heat shock proteins (Hsps) in acute cardiovascular diseases
[16], Hsp60 in stroke [17] and GAD in DM [18,19]. We have
reported that RPA2 antibodies increase in stroke [10].
SOSTDC1 and TUBB2C antibodies are associated with CI
and DM [11,12]. ATP2B4 and BMP-1 antibodies increase in
atherosclerosis-related diseases, such as CI, CAD, DM and
chronic kidney disease [13]. Adiponectin is a protein that is
closely and inversely associated with glucose tolerance and
atherosclerosis [1–9]. Thus, we examined the presence of
autoantibodies against adiponectin by the highly sensitive
AlphaLISA method, which produces highly reproducible
and stable results because it makes plate washing unnec‐
essary. This is the first report that confirms the presence of
adiponectin-Abs in sera. The levels of adiponectin-Abs
were significantly higher in patients with ACI, AMI and
DM than in the HD subjects (Figures 1–2, Table 1).
When the cut-off values were determined as the average +
2SD of the HD specimens, the positive rates of ACI were
somewhat higher than those of CAD (Table 1). However,
when the age-matched specimens of HD and patients were
compared, the positive rates were not apparently different.
Furthermore, AUC values and percentages of sensitivity
and specificity calculated by ROC analysis were quite
similar among CAD, ACI and DM (Figures 1–3). Taken
together, this suggests that adiponectin-Abs are almost
equally associated with these atherosclerosis-related
diseases.
Spearman’s correlation analysis was performed between
the adiponectin-Ab levels and the patients' data, including
age, gender, height, weight, BMI and blood pressure, using
the sera of patients with ACI from Rosai Hospital. Unex‐
pectedly, the antibody levels failed to show a significant
correlation with the patients' data (data not shown).
Therefore, the adiponectin-Ab levels may simply reflect
whether or not the patients suffer from atherosclerosis-
related diseases, such as CAD, ACI and DM.
In most cases, the development of autoantibodies is caused
by the overexpression of the particular corresponding
antigens [20–22]. The expression level of adiponectin itself
is negatively correlated with obesity, CAD and metabolic
disorders [5,6]. Namely, the adiponectin level decreases
during the progression of these diseases. On the other
hand, the autoantibodies increased in patients with
atherosclerosis-related diseases, such as ACI, AMI and DM
(Figures 1–3). This implies that the development of adipo‐
nectin-Abs did not simply result from antigen overexpres‐
sion but may play a causal and suppressive role in the
progression of atherosclerosis.
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The concentration of adiponectin in the sera of healthy
individuals ranges from 5–30 µg/mL [23], whereas the
concentration of adiponectin autoantibodies may be much
lower. Adiponectin can form a variety of multimer com‐
plexes, among which high-molecular weight multimers,
consisting of 12–18 monomers, cause anti-inflammatory,
anti-atherogenic and anti-diabetic effects [24,25]. If only
multimers consisting entirely of active monomers can
cause such effects, the function might be disturbed by the
binding of the antibody to a single monomer subunit. Thus,
a low autoantibody level may be able to affect adiponectin
function.
Because adiponectin has a causal role in the progression of
metabolic syndrome, DM, CAD and atherosclerosis,
several trials using adiponectin as a therapeutic agent have
been undertaken [26–28]. It may be necessary to take into
account the presence of anti-adiponectin-Abs, not only in
the diagnosis but also in the therapy of atherosclerosis-
related diseases.
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